EKF Diagnostics Cancels Over 13 Million Shares in Buyback Program

The latest announcement is out from EKF Diagnostics Holdings ( (GB:EKF) ).

EKF Diagnostics Holdings plc announced the cancellation of 13,710,698 ordinary shares as part of its share buyback program, effective from December 2, 2025. This cancellation reduces the company’s total issued share capital to 435,383,092 ordinary shares, each with one voting right, which will impact shareholders’ calculations under the FCA’s Disclosure and Transparency Rules.

The most recent analyst rating on (GB:EKF) stock is a Hold with a £27.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.

Spark’s Take on GB:EKF Stock

According to Spark, TipRanks’ AI Analyst, GB:EKF is a Neutral.

EKF Diagnostics Holdings receives a score of 67, driven by strong financial performance and a positive earnings call. The company’s robust balance sheet and improved profitability are significant strengths. However, technical indicators suggest potential bearish momentum, and the valuation is moderate. The positive outlook from the earnings call, including strategic growth plans and a share buyback program, enhances the overall score.

To see Spark’s full report on GB:EKF stock, click here.

More about EKF Diagnostics Holdings

EKF Diagnostics Holdings plc is an AIM-listed global diagnostics company that specializes in point-of-care analyzers for hematology and diabetes, as well as life sciences services that include the manufacture of enzymes and custom products for diagnostic, food, and industrial applications. The company is headquartered in Penarth, near Cardiff, and operates five manufacturing sites across the US and Germany, distributing its products to over 120 countries worldwide.

Average Trading Volume: 554,500

Technical Sentiment Signal: Strong Sell

Current Market Cap: £108.8M

For detailed information about EKF stock, go to TipRanks’ Stock Analysis page.